Pharmacological aspects of the antibiotics used for urological diagnostic procedures

References

• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mazzei T. Tissue penetration of antimicrobial agents. Insights into the treatment of serious infections. 1988;2(1):53–60.
   Google Scholar
• Mazzei T, Novelli A, Mini E, Periti P. Concentrazioni plasmatiche e tissutali degli antibiotici: qual è il loro valore predittivo? Ann Ital Med Int. 1992;7(3 Suppl):67S–73S.
   PubMedGoogle Scholar
• Periti P, Mazzei T. Principles of antimicrobial chemoprophylaxis in surgery. Chemioterapia. 1987;6(3):196–207.
   PubMedGoogle Scholar
• Mazzei T, Novelli A. Principi generali di farmacocinetica nella profilassi e terapia delle infezioni chirurgiche. In: Tonelli F, Periti P, editors. Preatti del II Simposio sul Controllo delle Infezioni in Chirurgia, Firenze: Edizioni Riviste Scientifiche; 1991. p. 36–40.
   Google Scholar
• Barza M. Principles of tissue penetration of antibiotics. J Antimicrob Chemother. 1981;8(Suppl C):7.
   PubMedGoogle Scholar
• Cars O. Pharmacokinetics of antibiotics in tissue and tissue fluids: a review. Scand J Infect Dis. 1990;74 (Suppl):23–33.
   Google Scholar
• Mazzei T, Periti P. Comparative evaluation of ceftriaxone tissue penetration. In: Hau T, Hell K, editors. Update on antibiotic prophylaxis in surgery. Basel: Kreis & Co Ltd; 1990. p. 17–22.
   Google Scholar
• Mazzei T, Novelli A, Reali EF, Periti P. Penetrazione tissutale di nuove betalattamine: valutazione comparativa mediante la tecnica delle vescicole da suzione. In: Dianzani F, Rondanelli EG, Schito G, Zampieri A, editors. Atti del ‘Progetto Finalizzato Controllo Malattie da Infezione’. Firenze: Il Sedicesimo 1988. p.465–8.
   Google Scholar
• Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturno GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(Suppl S1):i3-17.
   PubMedGoogle Scholar
• Benet LZ, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution and elimination. In: Gilman AG, Goodman LS, editors. The pharmacological basis of therapeutics, 7th edn, Appendis III. New York: Macmillan Publishers; 1985. p. 3–34.
   Google Scholar
• Naber KG, Sörgel F. Antibiotic therapy – rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia. 2003;35:331–5.
   PubMed Web of Science ®Google Scholar
• Bulitta JB, Kinzig M, Naber CK, Wagenlehner FME, Sauber C, Landersdorfer CB, et al. Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. Chemotherapy. 2011;57:402–16.
   PubMed Web of Science ®Google Scholar
• Naber CK, Hammer M, Kinzig-Schippers M, Sauber C, Sörgel F, Bygate EA, et al. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother. 2001;45(12):3524–30.
   PubMed Web of Science ®Google Scholar
• Grabe B, Bjerklund-Johanses TE, Botto H, Cek M, Naber KG, Pickard RS, et al. EAU Guidelines on Urological Infections. European Association of Urology, 2013.
   Google Scholar
• Grabe B, Bjerklund-Johanses TE, Botto H, Cek M, Naber KG, Pickard RS, et al. Oosterlinck W, Defoort R, Renders G. The concentration of sulphamethoxazole and trimethoprim in human prostate gland. Br J Urol. 1975;47(3):301–4.
   PubMedGoogle Scholar
• Concia E, Mazzei T, Schito GC, Bulfoni A, Costantino S, Di Rosa S, et al. Orientamenti terapeutici per il trattamento delle infezioni delle vie urinarie in medicina interna. Italian J Intern Med. 2003;2(1–Suppl 3):1–48.
   Google Scholar
• Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases, V Edizione edn. USA: Churchill Livingstone; 2000.
   Google Scholar
• Symes JM, Jarvis JD, Tresidder GC. An appraisal of cephalexin monohydrate levels in semen and prostatic tissue. Chemotherapy. 1974;20(5):257–62.
   PubMed Web of Science ®Google Scholar
• Litvak AS, Franks CD, Vaught SK, McRoberts JW. Cefazolin and cephalexin levels in prostatic tissue and sera. Urology. 1976;7(5):497–9.
   PubMedGoogle Scholar
• Naber KG, Madsen PO. Renal lymph concentrations of cephalosporins: the importance of protein binding and renal excretion. Infection. 1976;4(Suppl 2):S131–6.
   Google Scholar
• Smith RP, Schmid GP, Baltch AL, Sutphen NT, Hammer MC. Concentration of cefaclor in human prostatic tissue. Am J Med Sci. 1981;281(1):19–24.
   PubMed Web of Science ®Google Scholar
• Whitby M, Hempenstall J, Gilpin C, Weir L, Nimmo G. Penetration of monobactam antibiotics (aztreonam, carumonam) into human prostatic tissue. Chemotherapy. 1989;35(1):7–11.
   PubMed Web of Science ®Google Scholar
• Naber KG, Kinzig M, Adam D, Sörgel F, Bajorski AH, Kiehn R. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection. 1991;19(1):30–5.
   PubMed Web of Science ®Google Scholar
• Adam D, Schalkhäuser K, Boettger F. Diffusion of cefuroxime into the prostatic and other tissues of the urogenital region. Med Klin. 1979;74(49):1867–70.
   PubMedGoogle Scholar
• Grabe M, Andersson K-E, Forsgren A, Hellsten S. Concentrations of cefotaxime in serum, urine and tissues of urological patients. Infection. 1981;9(3):154–8.
   Web of Science ®Google Scholar
• Iversen P, Madsen PO. Short-term cephalosporin prophylaxis in transurethral surgery. Clin Ther. 1982;5(Suppl A):58–66.
   PubMedGoogle Scholar
• Adam D, Naber KG. Concentrations of ceftriaxone in prostate adenoma tissue. Chemotherapy. 1984;30(1):1–6.
   PubMed Web of Science ®Google Scholar
• Madsen PO, Dhruv R, Friedhoff LT. Aztreonam concentrations in human prostatic tissue. Antimicrob Agents Chemother. 1984;26(1):20–1.
   PubMed Web of Science ®Google Scholar
• Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1992;44(3):408–44.
   PubMed Web of Science ®Google Scholar
• Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28(4):275–86.
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073–81.
   PubMed Web of Science ®Google Scholar
• Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. J Am Med Assoc. 1998;279:125–9.
   PubMed Web of Science ®Google Scholar
• Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy. 2000;46(Suppl 1):6–14.
   PubMedGoogle Scholar
• Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis. 2001;32(Suppl 1):S39–46.
   PubMedGoogle Scholar
• Ambrose PG, Bhavani SM, Owens RE Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003;17(3):529–43.
   PubMed Web of Science ®Google Scholar
• Männistö PT, Karhunen M, Koskela O, Suikkari AM, Mattila J, Haataja H. Concentrations of tinidazole in breast milk. Acta Pharmacol Toxicol (Copenh). 1983;53(3):254–6.
   PubMedGoogle Scholar
• Boerma JBJ, Dalhoff A, Debruyne FMY. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31:13–8.
   PubMed Web of Science ®Google Scholar
• Lugg J, Lettieri J, Stass H, Agarwal V. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. J Chemother. 2008;20(2):213–8.
   PubMed Web of Science ®Google Scholar
• Periti P. Attualità delle cefalosporine nella chemioterapia antimicrobica. Farm Ter (Int J Drugs Ther). 2000;XVII(3/4):111–32.
   Google Scholar
• Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28(Suppl 1):S35–41.
   PubMedGoogle Scholar
• Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637–56.
   PubMed Web of Science ®Google Scholar
• Periti P, Rizzo M. Ruolo degli antibiotici orali in urologia diagnostica e terapeutica: la fosfomicina trometamolo. Farm Ter (Int J Drugs Ther). 2000;XVII(Suppl 2):3–29.
   Google Scholar
• Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54(5):1164–75.
   PubMed Web of Science ®Google Scholar
• Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34(5):407–13.
   PubMed Web of Science ®Google Scholar
• Schito GC, Gualco L, Naber KG, Botto H, Palou J, Mazzei T, et al. Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis? J Chemother. 2010;22(5):345–54.
   PubMed Web of Science ®Google Scholar
• Borghi CM, Laveneziana D, Riva A, Marca G, Zannini G. Concentrazioni nel siero e nel tessuto prostatico di fosfomicina con fosfomicina-trometamolo, nuovo derivato della fosfomicina con elevata biodisponibilità per somministrazione orale. Farm Ter (Int J Drugs Ther). 1986;III(3):216–20.
   Google Scholar
• Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton D, Zeglinski PT, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–5.
   PubMed Web of Science ®Google Scholar
• Zambon. Summary of Product Characteristics (Monouril SPC), date of revision of the text: October 23, 2013.
   Google Scholar